Astellas, Partner Aveo Rejected By U.S. FDA Panel For Kidney Cancer Drug
This article was originally published in PharmAsia News
Astellas Pharma and its non-Asia development partner Aveo Pharmaceuticals received a no vote from a U.S. FDA advisory committee for the Japan drug maker's tivozanib for treating kidney cancer.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.